{
    "nct_id": "NCT05573035",
    "official_title": "A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies",
    "inclusion_criteria": "* Age ≥ 18 years up to ≤ 75 years at the time of informed consent\n* Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) that is metastatic or locally advanced or unresectable and is relapsed and/or refractory (R/R) after standard therapy for each tumor histology\n* Participants must have received prior systemic treatment for their metastatic disease or locally advanced disease based on tumor type as follows:\n* Melanoma: participants with disease progression following an immune checkpoint inhibitor (CPI)\n* NSCLC: participants with disease progression following at least 1 approved systemic therapy, including an immune CPI-containing regimen for appropriate patients or an approved targeted therapy for known molecular abnormalities if applicable to their disease\n* CRC: participants with disease progression following at least 1 line of therapy, including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite instability (MSI) high/mismatch repair deficient (dMMR) CRC participants must have disease progression following systemic therapy with immune CPIs.\n* Measurable disease including at least 1 lesion that is safely resectable AND a target lesion to measure response and an additional lesion for biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ and marrow function\n* Women of childbearing potential must have a negative pregnancy test at screening\n* All participants must agree to practice highly effective methods of contraception\n* Fully recovered from toxicity from prior systemic anticancer therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Prior treatment with adoptive cellular therapy\n* Prior solid organ transplantation\n* Central nervous system (CNS) involvement of disease that is extensive, symptomatic or untreated, or patients with leptomeningeal disease\n* Uncontrolled or symptomatic pleural effusion or ascites\n* Untreated or active systemic infection\n* Active autoimmune disease requiring treatment or primary immunodeficiency syndrome\n* Systemic corticosteroids at a dose of >10 mg of prednisone or equivalent per day\n* Other primary malignancy within 3 years prior to enrollment\n* Impaired cardiac function or clinically significant cardiovascular disease\n* Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors\n* Pregnant or nursing (lactating) women",
    "miscellaneous_criteria": ""
}